BioSpace News Archive

The retirement of Mr. Christian Hogg after almost 22 years with the Company, including 15 years as Executive Director and Chief Executive Officer ; and the appointment of Dr. Weiguo Su, who has been with the Company for about 17 years, including about 10 years as Chief Scientific Officer and almost five years as Executive Director, as the new CEO.

GT Biopharma, Inc. announced that Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim CEO, will participate in a fireside chat in-person at the 34th Annual ROTH Conference on Tuesday March 15, 2022, at 8:30 AM PT.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that management will participate in two upcoming virtual investor conferences in March.

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced financial results for the year ended December 31, 2021.

Palatin Technologies, Inc. today announced that it will host a key opinion leader (KOL) webinar on the unmet medical need in treating patients with dry eye disease (DED) on Monday, March 7, 2022 at 10:30 am ET.

GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results and highlights for the fourth quarter and year ended December 31, 2021. Cash and cash equivalents at December 31, 2021 were $90.3 million.

Biomind Labs Announces Positive Results on in vivo Studies for Its Proprietary Drug Candidate BMND0.

CytoImmune Therapeutics, a clinical-stage cell-therapy company developing a novel class of tumor-reactive engineered natural killer cell-based cancer immunotherapies, today announced that the executive management team will participate in the Cowen’s 42nd Annual Health Care Conference.

Innoviva, Inc. (NASDAQ: INVA) (the “Company” or “Innoviva”) today announced the pricing of $225 million aggregate principal amount of the Company’s 2.125% convertible senior notes due 2028 (the “Notes”).

StageZero Life Sciences, Ltd. is pleased to announce that it has closed its previously announced private placement of its common shares and warrants to purchase Common Shares with an institutional investor for gross proceeds of approximately CAD$1.87 million.